✦ LIBER ✦

[572] RANDOMIZED, OPEN LABEL TRIAL COMPARING EFFICACY AND SAFETY OF PEGYLATED INTERFERON ALFA 2b VS ALFA 2b TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH NON 2/3 GENOTYPES - FINAL ANALYSIS

✍ Scribed by H. Berak; A. Kolakowska-Rzadzka; M. Wasilewski; J. Kowalska; J.J. Stanczak; K. Bardadin; A. Horban

Book ID: 117375664
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 275 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62170-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of Chronic Hepatitis due to He

Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin—A Multicenter Study

✍ Subrat K Acharya; V Sreenivas; Siddharth Datta Gupta; Shakti Kumar; Yogesh K Cha 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 186 KB

[573] COMPARISON OF EARLY VIROLOGIC RESP

[573] COMPARISON OF EARLY VIROLOGIC RESPONSE AMONG PATIENTS WITH CHRONIC HEPATITIS C INFECTED WITH GENOTYPE NON 2/3 TREATED WITH PEGYLATED INTERFERON ALFA-2b AND RIBAVIRIN IN DEPENDENCE WITH HEPATIC FIBROSIS STAGES

✍ H. Berak; A. Kolakowska-Rzadzka; M. Wasilewski; J. Kowalska; I. Stanczak; K. Bar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 140 KB

Efficacy of 24 weeks treatment with pegi

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

✍ Stefan Zeuzem; Maria Buti; Peter Ferenci; Jan Sperl; Yves Horsmans; Janusz Cianc 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 116 KB

Efficacy of boceprevir, an NS3 protease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB

Better efficacy of a 12-month interferon

Better efficacy of a 12-month interferon alfa-2b retreatment in patients with chronic hepatitis C relapsing after a 6-month treatment: A multicenter, controlled, randomized trial

✍ Jean-Louis Payen; Jacques Izopet; Virginie Galindo-Migeot; Valérie Lauwers-Cance 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 320 KB 👁 2 views

We studied the efficacy of three interferon alfa-2b (IFN-2b) regimens for the retreatment of patients with chronic hepatitis C (CHC) with prior complete response followed by relapse. Consecutive patients with CHC who had a complete biochemical response but relapse after a first course of 6 months of

14 EFFICACY AND SAFETY OF WEIGHT-BASED R

14 EFFICACY AND SAFETY OF WEIGHT-BASED REGIMENS OF TARIBAVIRIN OR RIBAVIRIN, GIVEN WITH PEGINTERFERON ALFA-2B, AT 12 WEEKS AFTER TREATMENT (SVR12) IN NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC-HEPATITIS C

✍ F. Poordad; E. Lawitz; R. Pozza; M. Shiffman; B. Bacon; E. Godofsky; D. Halliman 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 47 KB